Literature DB >> 17518546

Allotopic mRNA localization to the mitochondrial surface rescues respiratory chain defects in fibroblasts harboring mitochondrial DNA mutations affecting complex I or v subunits.

Crystel Bonnet1, Valérie Kaltimbacher, Sami Ellouze, Sébastien Augustin, Paule Bénit, Valérie Forster, Pierre Rustin, José-Alain Sahel, Marisol Corral-Debrinski.   

Abstract

The possibility of synthesizing mitochondrial DNA (mtDNA)-coded proteins in the cytosolic compartment, called allotopic expression, provides an attractive option for genetic treatment of human diseases caused by mutations of the corresponding genes. However, it is now appreciated that the high hydrophobicity of proteins encoded by the mitochondrial genome represents a strong limitation on their mitochondrial import when translated in the cytosol. Recently, we optimized the allotopic expression of a recoded ATP6 gene in human cells, by forcing its mRNA to localize to the mitochondrial surface. In this study, we show that this approach leads to a long-lasting and complete rescue of mitochondrial dysfunction of fibroblasts harboring the neurogenic muscle weakness, ataxia and retinitis Pigmentosa T8993G ATP6 mutation or the Leber hereditary optic neuropathy G11778A ND4 mutation. The recoded ATP6 gene was associated with the cis-acting elements of SOD2, while the ND4 gene was associated with the cis-acting elements of COX10. Both ATP6 and ND4 gene products were efficiently translocated into the mitochondria and functional within their respective respiratory chain complexes. Indeed, the abilities to grow in galactose and to produce adenosine triphosphate (ATP) in vitro were both completely restored in fibroblasts allotopically expressing either ATP6 or ND4. Notably, in fibroblasts harboring the ATP6 mutation, allotopic expression of ATP6 led to the recovery of complex V enzymatic activity. Therefore, mRNA sorting to the mitochondrial surface represents a powerful strategy that could ultimately be applied in human therapy and become available for an array of devastating disorders caused by mtDNA mutations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17518546     DOI: 10.1089/rej.2006.0526

Source DB:  PubMed          Journal:  Rejuvenation Res        ISSN: 1549-1684            Impact factor:   4.663


  28 in total

Review 1.  Mitochondrial medicine: to a new era of gene therapy for mitochondrial DNA mutations.

Authors:  Hélène Cwerman-Thibault; José-Alain Sahel; Marisol Corral-Debrinski
Journal:  J Inherit Metab Dis       Date:  2010-06-23       Impact factor: 4.982

2.  Differential targeting of VDAC3 mRNA isoforms influences mitochondria morphology.

Authors:  Morgane Michaud; Elodie Ubrig; Sophie Filleur; Mathieu Erhardt; Geneviève Ephritikhine; Laurence Maréchal-Drouard; Anne-Marie Duchêne
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-02       Impact factor: 11.205

Review 3.  The approaches for manipulating mitochondrial proteome.

Authors:  Inna N Shokolenko; Mikhail F Alexeyev; Susan P LeDoux; Glenn L Wilson
Journal:  Environ Mol Mutagen       Date:  2010-06       Impact factor: 3.216

Review 4.  Emerging therapies for mitochondrial diseases.

Authors:  Michio Hirano; Valentina Emmanuele; Catarina M Quinzii
Journal:  Essays Biochem       Date:  2018-07-20       Impact factor: 8.000

5.  A single mutation in the first transmembrane domain of yeast COX2 enables its allotopic expression.

Authors:  Lubica Supekova; Frantisek Supek; John E Greer; Peter G Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-01       Impact factor: 11.205

6.  Optimized allotopic expression of the human mitochondrial ND4 prevents blindness in a rat model of mitochondrial dysfunction.

Authors:  Sami Ellouze; Sébastien Augustin; Aicha Bouaita; Crystel Bonnet; Manuel Simonutti; Valérie Forster; Serge Picaud; Jose-Alain Sahel; Marisol Corral-Debrinski
Journal:  Am J Hum Genet       Date:  2008-09-04       Impact factor: 11.025

Review 7.  Is there treatment for Leber hereditary optic neuropathy?

Authors:  Jason H Peragallo; Nancy J Newman
Journal:  Curr Opin Ophthalmol       Date:  2015-11       Impact factor: 3.761

Review 8.  Treatment of hereditary optic neuropathies.

Authors:  Nancy J Newman
Journal:  Nat Rev Neurol       Date:  2012-09-04       Impact factor: 42.937

9.  Leber's Hereditary Optic Neuropathy-Gene Therapy: From Benchtop to Bedside.

Authors:  Rajeshwari D Koilkonda; John Guy
Journal:  J Ophthalmol       Date:  2010-12-26       Impact factor: 1.909

Review 10.  Mitochondrial genetics.

Authors:  Patrick Francis Chinnery; Gavin Hudson
Journal:  Br Med Bull       Date:  2013-05-22       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.